Interrater Reliability of NI-RADS on Posttreatment PET/Contrast-enhanced CT Scans in Head and Neck Squamous Cell Carcinoma

dc.contributor.authorHsu, Derek
dc.contributor.authorRath, Tanya J.
dc.contributor.authorBranstetter, Barton F., IV.
dc.contributor.authorAnzai, Yoshimi
dc.contributor.authorPhillips, C. Douglas
dc.contributor.authorJuliano, Amy F.
dc.contributor.authorMosier, Kristine M.
dc.contributor.authorBazylewicz, Michael P.
dc.contributor.authorPoliashenko, Stan M.
dc.contributor.authorKulzer, Matthew H.
dc.contributor.authorRhyner, Patricia A.
dc.contributor.authorRisk, Benjamin
dc.contributor.authorWiggins, Richard H.
dc.contributor.authorAiken, Ashley H.
dc.contributor.departmentRadiology and Imaging Sciences, School of Medicineen_US
dc.date.accessioned2023-01-03T16:55:01Z
dc.date.available2023-01-03T16:55:01Z
dc.date.issued2021-05
dc.description.abstractPurpose: To evaluate the interrater reliability among radiologists examining posttreatment head and neck squamous cell carcinoma (HNSCC) fluorodeoxyglucose PET/contrast-enhanced CT (CECT) scans using Neck Imaging Reporting and Data System (NI-RADS). Materials and Methods: In this retrospective study, images in 80 patients with HNSCC who underwent posttreatment surveillance PET/CECT and immediate prior comparison CECT or PET/CECT (from June 2014 to July 2016) were uploaded to the American College of Radiology's cloud-based website, Cortex. Eight radiologists from seven institutions with variable NI-RADS experience independently evaluated each case and assigned an appropriate prose description and NI-RADS category for the primary site and the neck site. Five of these individuals were experienced readers (> 5 years of experience), and three were novices (< 5 years of experience). In total, 640 lexicon-based and NI-RADS categories were assigned to lesions among the 80 included patients by the eight radiologists. Light generalization of Cohen κ for interrater reliability was performed. Results: Of the 80 included patients (mean age, 63 years ± 10 [standard deviation]), there were 58 men (73%); 60 patients had stage IV HNSCC (75%), and the most common tumor location was oropharynx (n = 32; 40%). Light κ for lexicon was 0.30 (95% CI: 0.23, 0.36) at the primary site and 0.31 (95% CI: 0.24, 0.37) at the neck site. Light κ for NI-RADS category was 0.55 (95% CI: 0.46, 0.63) at the primary site and 0.60 (95% CI: 0.48, 0.69) at the neck site. Percent agreement between lexicon and correlative NI-RADS category was 84.4% (540 of 640) at the primary site and 92.6% (593 of 640) at the neck site. There was no significant difference in interobserver agreement among the experienced versus novice raters. Conclusion: Moderate agreement was achieved among eight radiologists using NI-RADS at posttreatment HNSCC surveillance imaging.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationHsu D, Rath TJ, Branstetter BF, et al. Interrater Reliability of NI-RADS on Posttreatment PET/Contrast-enhanced CT Scans in Head and Neck Squamous Cell Carcinoma. Radiol Imaging Cancer. 2021;3(3):e200131. doi:10.1148/rycan.2021200131en_US
dc.identifier.urihttps://hdl.handle.net/1805/30827
dc.language.isoen_USen_US
dc.publisherRadiological Society of North Americaen_US
dc.relation.isversionof10.1148/rycan.2021200131en_US
dc.relation.journalRadiology Imaging Canceren_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourcePMCen_US
dc.subjectCTen_US
dc.subjectPETen_US
dc.subjectHeaden_US
dc.subjectNecken_US
dc.subjectNeoplasms-Primaryen_US
dc.subjectObserver Performanceen_US
dc.titleInterrater Reliability of NI-RADS on Posttreatment PET/Contrast-enhanced CT Scans in Head and Neck Squamous Cell Carcinomaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
rycan.2021200131.pdf
Size:
565.81 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: